

Harding et al. The Lancet Oncology, 2023; 24, 772-782

[Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer \(HERIZON-BTC-01\): a multicentre, single-arm, phase 2b study - The Lancet Oncology](#)